Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib

Keizman D., Sarid D., Lee J. L., Sella A., Gottfried M., Hammers H., ...Daha Fazla

ONCOLOGIST, cilt.21, sa.10, ss.1212-1217, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 10
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1634/theoncologist.2015-0428
  • Dergi Adı: ONCOLOGIST
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1212-1217
  • Anahtar Kelimeler: Metastatic renal cell carcinoma, Chromophobe type, Clear cell type, Outcome, Sunitinib, PROGRESSION-FREE, SURVIVAL, EFFICACY, TRIAL
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background. Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC.